StreetAlpha.app
Home › Stocks › AQST

Aquestive Therapeutics, Inc. (AQST)

Healthcare
$3.70
▼ −1.60%
LAST CLOSE · NOV 17

Aquestive develops oral film drug delivery technology and medicines for patients and pharmaceutical partners. It last closed at $3.70 on Nov 17, down 1.60% on the day. AQST last reported earnings on Tue, Aug 11, 2026. In the past 30 days there were 1 dark pool print totaling $256K, the largest $256K.

AI Auto Pilots
Is AQST in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$48.8M
+12.5% vs a year ago
Net income
−$79.3M
−162.3% margin
EPS (diluted)
−$0.65
Free cash flow
−$40.7M
−83.3% margin
Valuation
Market cap
$465.0M
125.7M shares
P/E
–
No P/E while losing money
Price to sales
9.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$90.3M
At Sep 30
Debt
$55.0M
At Sep 30
Shareholder equity
−$70.8M
Shares outstanding
125.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $50.8M$50.8MFY2021FY2022: $47.7M$47.7MFY2022FY2023: $50.6M$50.6MFY2023FY2024: $57.6M$57.6MFY2024FY2025: $44.5M$44.5MFY2025

From AQST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · After the close (AMC)
Reported EPS
-$0.18
vs -$0.10 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±12.5%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated AQST in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 170.3% upside

Based on 1 analyst who set a price target on AQST in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $3.70.

$3$6$8$11PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $10AVG $10LOW $10Jun 18LAST CLOSE+12 MO$3$6$8$11PAST 10 DAYSTARGETSHIGH $10AVG $10LOW $10Jun 18LAST CLOSE+12 MO
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 24Buy$10
DateFirmActionRatingPrice target
Aug 24HC Wainwright & Co.ReiteratedBuy$10
Loading…

Technical Analysis

AQST · as of the Nov 17 close · updated after every close
Downtrend

The stock is 4% below its 20 day and 16% below its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the swing low (Oct 19) at $3.65, and the nearest resistance the Pivot at $3.72.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 6.4%/day
Key levels
$6.7452 week high+82.2%
$4.32100 day average+16.8%
$4.3150 day average+16.5%
$4.23200 day average+14.3%
$4.18Swing high (Jul 20)+13.0%
$3.8420 day average+3.8%
$3.79Pivot R1+2.4%
$3.72Pivot+0.5%
$3.70Last close
$3.65Swing low (Oct 19)−1.4%
$3.64Pivot S1−1.6%
$2.9352 week low−20.8%
Indicators
RSI (14)41.83Middle of its rangeNeutral
MACD-0.18Above its signal lineBullish
Stochastic45.6Middle of its rangeNeutral
ADX (14)25.0Trending down
Williams %R-64.1Oversold below −80, overbought above −20Neutral
CCI (20)-46.5Oversold below −100, overbought above 100Neutral
Rate of change−4.6%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 6.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AQST

What happened before

See how AQST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AQST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AQST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AQST in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$256K
Largest print
$256K
Loading…

AQST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲90 buying vs 78 selling
  • ▲Held by funds +2.9 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191186+2.7%
In funds' top 1032+50.0%
Held by funds60.2%57.3%+2.9 pts
New / increased24 / 6623 / 69−2.2%
Reduced / sold out57 / 2143 / 21+21.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AQST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AQST is in one of them and how their past AQST trades turned out.

AQST in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AQST in an article yet. Here's the latest on the wider market.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines using oral film and other drug delivery technologies. Its PharmFilm product is a thin film that dissolves in the mouth, and it is used to deliver prescription medicines. The company is developing Anaphylm, an epinephrine treatment for severe allergic reactions that dissolves under the tongue. It also manufactures licensed products that partner companies sell to patients and physicians. Aquestive is headquartered in Warren, New Jersey, and produces its products at a facility in Portage, Indiana.

Headquarters
Warren, NJ